Trial Profile

The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary) ; Heparin
Indications Catheter thrombosis
Focus Therapeutic Use
Acronyms D-Fine
Sponsors Boehringer Ingelheim

Most Recent Events

31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
17 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
17 Aug 2010 Actual patient number is 53 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com